Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.
The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
Semaglutide in type 2 diabetes with chronic kidney disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Furthermore, semaglutide also significantly reduced the rate of eGFR decline (annual slope difference 1•16 mL/min per 1•73 m², 0•86-1•47), MACE (HR 0•82, 0•68-0•98), and all-cause mortality (HR 0•80, 0•67-0•95)”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [26]
In the citing paper
“Treatment with injectable semaglutide 1 mg once weekly reduced the relative risk for the composite primary outcome (ie, ≥50% eGFR decline, eGFR <15 mL/min per 1•73 m², dialysis or transplant, or death due to kidney disease or cardiovascular disease) by 24% compared with placebo (HR 0•76, 0•66-0•88).26”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [26]
In the citing paper
“Moreover, the GLP-1 receptor agonist, semaglutide reduced the risk of a composite kidney end point in a dedicated kidney outcome trial.11”
From The Effect of Retatrutide on Kidney Parameters in Participants With Type 2 Diabetes Mellitus and/or Obesity (2025) · cites this paper as [11]
In the citing paper
“semaglutide can reduce the progression of chronic kidney disease in patients with and without diabetes and even in those taking SGLT2 inhibitors [12–14].”
From New drugs for the treatment of obesity: do we need approaches to preserve muscle mass? (2025) · cites this paper as [13]
In the citing paper
“Once-weekly treatment with 1 mg semaglutide reduced the risk of the primary composite outcome by 24% and delayed the progression of kidney dysfunction over a period of 4 years (75).”
From Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits (2025) · cites this paper as [75]
35 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
A New Equation to Estimate Glomerular Filtration Rate
Levey, A. S., Stevens, L. A., Schmid, C. H., Zhang, Y. (., Castro, A. F., Feldman, H. I., Kusek, J. W., Eggers, P., Van Lente, F., Greene, T., et al. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-9-200905050-00006 · Cited by 25,603
KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease
Stevens, P. E., Ahmed, S. B., Carrero, J. J., Foster, B., Francis, A., Hall, R. K., Herrington, W. G., Hill, G., Inker, L. A., Kazancıoğlu, R., et al. (2024) · Kidney International · doi:10.1016/j.kint.2023.10.018 · Cited by 8,530
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493
Bikbov, B., Purcell, C. A., Levey, A. S., Smith, M., Abdoli, A., Abebe, M., Adebayo, O. M., Afarideh, M., Agarwal, S. K., Agudelo-Botero, M., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30045-3 · Cited by 6,648
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189
Self-citationLewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R., & Raz, I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011303 · Cited by 5,987
Dapagliflozin in Patients with Chronic Kidney Disease
Heerspink, H. J. L., Stefánsson, B. V., Correa-Rotter, R., Chertow, G. M., Greene, T., Hou, F.-F., Mann, J. F. E., McMurray, J. J. V., Lindberg, M., Rossing, P., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2024816 · Cited by 5,618
Self-citationEffect of finerenone on chronic kidney disease outcomes in type 2 diabetes
Bakris, G. L., Agarwal, R., Anker, S. D., Pitt, B., Ruilope, L. M., Rossing, P., Kolkhof, P., Nowack, C., Schloemer, P., Joseph, A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2025845 · Cited by 2,935
Self-citationEmpagliflozin in Patients with Chronic Kidney Disease
The EMPA-KIDNEY Collaborative Group (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2204233 · Cited by 2,754
Cardiovascular events with finerenone in kidney disease and type 2 diabetes
Pitt, B., Filippatos, G., Agarwal, R., Anker, S. D., Bakris, G. L., Rossing, P., Joseph, A., Kolkhof, P., Nowack, C., Schloemer, P., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2110956 · Cited by 1,814
Self-citation
Cited by
Items 1,001–1,100 of 1,871
How should we best manage the consequences of nephron loss in IgAN?
Kim, J., Kamal, F., Yeung, B., & Lafayette, R. A. (2025) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfaf225 · Cited by 1
Heinzl, M. W., Resl, M., Maier, J., Steinwender, C., Falkensammer, J., Fellinger, P., Steinmaurer, T., Saely, C. H., Hoppichler, F., Stingl, H., et al. (2026) · Wiener klinische Wochenschrift · doi:10.1007/s00508-025-02667-8 · Cited by 1
“…da sich hieraus auch direkte the-rapeutische Konsequenzen ergeben (Initiierung eines SGLT-2-Hemmers, ACE-Hemmer oder Angiotensin-Rezeptorblocker mit Hochtitration zur maximal ver-träglichen Dosis, Finerenon sowie nach Möglichkeit Initiierung eines Inkretin-Mimetikums [Semaglutid]) [56, 57].”
Hasan, I., Bessette, L. G., Jacquemyn, X., Wang, Y., subramaniam, K., Hasan, Z., Thoma, F. W., Ogami, T., Bonatti, J. O., Kaczorowski, D., et al. (2026) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2026.02.005 · Cited by 2
Skalsky, K., Romi, M., Shiyovich, A., et al. (2025) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd12040133 · Cited by 1
“This includes sodium–glucose cotransporter 2 inhibitors (SGLT2Is) [30,31], glucagon-like peptide receptor agonists (GLP1RAs) [32,33] and nonsteroidal mineralocorticoid receptor antagonists (MRAs) [34,35].”
Beyond the prescription: A holistic GP approach to obesity and weight loss medications
Tyler, B. (2026) · InnovAiT Education and inspiration for general practice · doi:10.1177/17557380261420769 · Cited by 1
The transformative breakthroughs in GLP-1 research recognized by the 2024 Lasker~DeBakey award
Zhou, Y.-F., Li, Q., Wang, L.-G., Lu, Y., Wang, Y., & Yang, J. (2024) · Current Medicine · doi:10.1007/s44194-024-00041-w · Cited by 1
“…inflammation in patients with obesity-related heart failure with preserved ejection fraction (HFpEP), and decrease the risk of major kidney disease events and cardiovascular-related mortality in patients with type 2 diabetes and chronic kidney disease(Butler et al 2024; Perkovic et al 2024) (Fig.”
Cohen, C. M., Mosenzon, O., Aharonovich, A., Karasik, A., & Schechter, M. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112086 · Cited by 4
Porterfield, L. R., Nadeem, S., Swanson, D., Hayek, S. S., & Vaughan, E. M. (2026) · Current Atherosclerosis Reports · doi:10.1007/s11883-026-01448-6 · Cited by 2
“…now have dedicated hard-endpoint evidence: in the FLOW trial, semaglutide reduced the primary composite kidney outcome (≥ 50% eGFR decline, kidney failure, or kidney or cardiovascular death) by 24% (hazard ratio 0.76, 95% CI 0.66–0.88) in type 2 diabetes and CKD and slowed eGFR decline [ 48 , 49].”
InfluentialRisk of End-Stage Kidney Disease and Topiramate Use
Halimi, J., Maisons, V., de Fréminville, J.-B., Roger, S., Bisson, A., Chadet, S., & Fauchier, L. (2025) · Kidney International Reports · doi:10.1016/j.ekir.2025.06.003 · Cited by 1
Lama, S., Chaudhuri, S., Blankenship, D. M., Ban, A. N., Usvyat, L. A., Pecoits-Filho, R., & Hippen, B. E. (2026) · Kidney Medicine · doi:10.1016/j.xkme.2026.101476 · Cited by 1
“The Evaluate Renal Function with Semaglutide Once Weekly (FLOW) trial 6 and the Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity (SELECT) trial 7 demonstrated a significant reduction in MACE in patients with CKD prescribed semaglutide compared with placebo.”
Zhang, Z., Qu, Y., Wang, X., Ji, Y., Yao, J., Deng, W., Sun, G., Xu, H., Chen, X., & Hong, Q. (2026) · Research · doi:10.34133/research.1386 · Cited by 3
“Data from cardiovascular outcome trials and the FLOW trial indicate that GLP-1RA therapy reduces albuminuria progression and improves kidney outcomes, although their renal protective effects remain less extensively validated compared with SGLT2 inhibitors [ 155 , 156 ].”
Mitochondrial Alterations and CKD: A Review
Pinzón-Cortés, J. A., Narongkiatikhun, P., Yuan, L., Meister, J., Hampson, H., van Raalte, D. H., Blondin, D. P., Capozzi, M. E., Sweet, I. R., Nelson, R. G., et al. (2026) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2026.01.021 · Cited by 2
McIntyre, R. S., Zhang‐James, Y., Goldberg, J. F., & Kwan, A. T. H. (2026) · medRxiv · doi:10.64898/2026.02.09.26345925 · Cited by 1
Marzano, F., Paolillo, S., Gargiulo, P., Cotticelli, C., Santo, M. D., Nardi, E., Abbellito, G. M., Liccardi, L., Filardi, F. P., Bruzzese, D., et al. (2026) · Cardiovascular Diabetology · doi:10.1186/s12933-026-03215-y · Cited by 4
“Finally, in three trials [4, 8, 9], patients treated with semaglutide showed a 30% lower incidence of MALE, consistently defined in all three studies.”
InfluentialSzczuko, M., Grudniewska, A., Durma, A. C., Małecki, R., Filipczyńska, I., Franek, E., & Kędzierska-Kapuza, K. (2025) · Nutrients · doi:10.3390/nu17132112 · Cited by 3
“The disease is associated with high mortality and poses a huge challenge to public health worldwide, urgently necessitating new strategies for protecting against DKD and slowing the progression of chronic kidney disease (CKD) in the course of diabetes mellitus (DM) [4,5].”
End Stage Kidney Disease in Cystic FibrosisPreprint
Stevanovic, M., MacKenzie, T. A., Zimmerman, A. M., & Graber, M. L. (2024) · medRxiv · doi:10.1101/2024.09.19.24313925 · Cited by 1
“Despite the recognized nephrotoxicity of these agents, previous studies have been inconclusive concerning the contribution of cumulative aminoglycoside exposure to CKD in CF 33,34 .”
BackgroundDisease modifying therapies in diabetes and endocrinology
Mathieu, C. (2024) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00336-x · Cited by 1
Barber, T., Neumiller, J. J., Fravel, M. A., Page, R. L., II, & Tuttle, K. R. (2025) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxaf045 · Cited by 2
Self-citationChronic Kidney Disease-Part 2: Management and Its Complications
Kramer, H. (2025) · Advances in Kidney Disease and Health · doi:10.1053/j.akdh.2024.11.004 · Cited by 1
GLP ‐1 Receptor Agonists for Treating Alcohol Use Disorder: A Critical Review
Woo, S., Zhu, G., Castro, C., Phuong, A., Roy, A., Davis, C. N., & Kranzler, H. R. (2026) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.70312 · Cited by 3
Zhao, W., Niu, X., Zhou, X., Shi, R., & Zhou, X. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-33885-4.00007-x · Cited by 1
Ling, J., & Chow, E. (2024) · Med · doi:10.1016/j.medj.2024.06.010 · Cited by 2
Xiao-yu, Z., Deng, C.-H., Zhong, J.-Y., Wu, Q., Chen, Q.-X., Gao, X.-Y., Xu, Y., Jiang, Z., Guo, M., & Teng, F. (2026) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2026.104859 · Cited by 1
Beyond Blood Pressure: Salt Sensitivity as a Cardiorenal Phenotype—A Narrative Review
Bachlitzanaki, M., Aletras, G., Bachlitzanaki, E., Vasilaki, N., Lydakis, C., Petrakis, I., Foukarakis, E. G., & Stylianou, K. (2026) · Life · doi:10.3390/life16020247 · Cited by 4
Levy, N., NERLINO, K., BONGALOS, S., Dasilva, A., UZOR, C., Liang, Y. J., & SONUBI, O. (2026) · JMIR Formative Research · doi:10.2196/76993 · Cited by 1
The year in cardiovascular medicine 2024: the top 10 papers in diabetes and metabolic disorders
Cosentino, F., Cannon, C. P., & Marx, N. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf280 · Cited by 1
Simultaneous Pancreas and Kidney Transplantation in Patients With Type 2 Diabetes Mellitus
Owen, R. V., Reynard, J., Thompson, E., Kourounis, G., Snowden, C. P., Maillo-Nieto, A., Shaw, J., Wilson, C. H., & White, S. A. (2025) · Transplant International · doi:10.3389/ti.2025.14772 · Cited by 2
“A US trial (the FLOW trial) evaluated the impact of Semaglutide use in patients with T2DM and an eGFR between 25 and 75 mL/min/1.73 m 2 [66].”
InfluentialA decade of SGLT2 inhibitors: Lessons learned and the road ahead in type 2 diabetes
Kimura, T., & Kaku, K. (2025) · Journal of Diabetes Investigation · doi:10.1111/jdi.70187 · Cited by 1
“Renal protection is a well-established effect of SGLT2 inhibitors, while recent reports on renal composite outcomes with semaglutide have drawn increasing attention to glucagon-like peptide-1 (GLP-1) receptor agonists 10 .”
Liu, M. R., Cheng, Z. F., Li, L., Cai, H., Liu, J., Liu, J., Zheng, Y., Wang, S., Zhao, J., Yang, W., et al. (2026) · Annals of Internal Medicine · doi:10.7326/annals-25-04623 · Cited by 1
Stamatiou, A., Theodorakopoulou, M. P., Iatridi, F., Koufakis, T., Kotsa, K., & Sarafidis, P. A. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70997 · Cited by 2
“Among studies with insufficient reported data, no significant differences between semaglutide and placebo were observed [34, 39].”
InfluentialGlucagon-like Peptide 1 Receptor Agonist Use in Hospital: A Multicentre Observational Study
Ray, P., Moggridge, J. A., Weisman, A., Tadrous, M., Drucker, D. J., Perkins, B. A., & FRALICK, M. (2024) · Canadian Journal of Diabetes · doi:10.1101/2024.08.01.24311352 · Cited by 1
SGLT2i and GLP1RA effects in patients followed in a hospital diabetology consultation
Lopes, A. C., Lourenço, O. M., & Morgado, M. (2024) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2024.2421872 · Cited by 1
“This real-world evidence aligns with controlled trial data and provides reassurance regarding the long-term safety of these agents [11,12,51,52].”
Shang, Y., Jin, J., & He, Q. (2026) · Diabetes Care · doi:10.2337/dc26-1227 · Cited by 1
Brunel, F. M., Parlee, S. D., Li, P., Lu, W., Chabenne, J. R., Pérez–Tilve, D., Finan, B., Kharitonenkov, A., & DiMarchi, R. D. (2026) · Biochemistry · doi:10.1021/acs.biochem.5c00820 · Cited by 2
Posicionamento sobre a Saúde Cardiometabólica ao Longo do Ciclo de Vida da Mulher – 2025
de Oliveira, G. M. M., de Almeida, M. C. C., Valério, C. M., Giuffrida, F. M. A., Espíndola, L. N., Izar, M. C. D. O., Marques-Santos, C., Freire, C. M. V., Albuquerque, C. J. D. M., Chagas, A. C. P., et al. (2025) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20250615 · Cited by 5
MASLD: Lipotoxicity and Imaging Parallels from Liver Steatosis to Kidney Injury
Săndulescu, S. M., Ghiga, D. Ș., Tudoraşcu, D. R., Săndulescu, L., Mită, A., Urhuț, M. C., & Taisescu, C. I. (2025) · Life · doi:10.3390/life15121805 · Cited by 5
“These hepatic benefits parallel renal gains: the FLOW trial demonstrated that semaglu-tide reduces clinically important kidney outcomes and cardiovascular death in T2DM with CKD [147].”
Efficacy and safety of semaglutide in patients with heart failure: A meta-analysis
Li, X., Liu, G., & Liu, Y. (2025) · Precision medication. · doi:10.1016/j.prmedi.2025.100064 · Cited by 1
Wright, E. E., Cuenca, A. M. C., & Ngui, D. (2025) · Clinical Diabetes · doi:10.2337/cd25-0013 · Cited by 2
SOUL searching in GLP-1 therapy: Oral semaglutide confirms cardioprotection in type 2 diabetes
Andreasen, C. R., & Vilsbøll, T. (2025) · Med · doi:10.1016/j.medj.2025.100774 · Cited by 1
Shah, P. P., & Bhattacharya, R. (2026) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2026.101418 · Cited by 2
“Renal protection was shown in the FLOW trial, where weekly semaglutide slowed CKD progression in T2DM [24,25].”
Nephrology: What You May Have Missed in 2024
Alfadhel, A., Alfarsi, R., Alkhajah, H., Collins, J., & Sehgal, A. R. (2025) · Annals of Internal Medicine · doi:10.7326/annals-25-00796 · Cited by 1
Wang, Y., Feng, L., Wang, Y., Li, B., Liang, N., Song, X., Qin, J., Zhang, M., & Li, Y. (2026) · Renal Failure · doi:10.1080/0886022x.2026.2620155 · Cited by 2
“in 5 trials [18,23,24,28,29] with available data specifically for 21,205 patients, a total of 1,909 patients experienced all-cause mortality events, and the risk was significantly lower in the GLP-1Ras group compared with the placebo group (RR, 0.83; 95% ci, 0.76 to 0.90, I 2 = 0%, p < 0.01) (shown…”
InfluentialZawadka, M., Taguiam, E., Lê, M., Sanjanwala, R., Liu, S., Shah, A. H., & Kunutsor, S. K. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70411 · Cited by 6
Diabetes Mellitus in Kidney Transplant Recipients and New Hypoglycemic Agent Options
Bartoli, G., Strologo, A. D., Arena, M. G., Ceravolo, M. J., Mitterhofer, A. P., Pesce, F., & Grandaliano, G. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26135952 · Cited by 4
“In recent years, several clinical trials demonstrated that GLP1RAs reduce the risk of major CV events and CKD progression in DM patients [25,74–77].”
From the SELECT study to SOUL: different administration methods of semaglutide but same efficacy?
Gatto, L., Biccirè, F. G., Lentini, A. E., Scalia, L., & Prati, F. (2025) · European Heart Journal Supplements · doi:10.1093/eurheartjsupp/suaf024 · Cited by 2
The GLP-1 receptor agonist revolution comes to nephrology
Thomas, M. C., & Cooper, M. E. (2024) · Nature Reviews Nephrology · doi:10.1038/s41581-024-00876-4 · Cited by 2
“A subsequent formal analysis demonstrated that the risk of this primary composite end point was 24% lower in the semaglutide group than in the placebo group (331 versus 410 first events; hazard ratio (HR), 0.76; 95% confidence interval (CI), 0.66–0.88; P = 0.0003) 1 .”
InfluentialSURPASS ‐ CVOT and the Emerging Biology of Cardiometabolic Benefit
Corrao, S., Cosentino, F., & Federici, M. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71175 · Cited by 1
“…OUTCOME demonstrated cardiovascular benefit dominated not by recurrent myocardial infarction but by cardiovascular mortality and heart failure hospitalisation [14], a discordance that subsequently reshaped the endpoint architecture of cardio-renal trials including EMPEROR, DAPA-HF and FLOW [15].”
Exosomes applications in kidney diseases
Li, D., Feng, P., Wang, Y., et al. (2025) · Molecular Biology Reports · doi:10.1007/s11033-025-10727-5 · Cited by 1
Hamayal, M., Akhtar, C. H., Ahmad, N., Awwab, M., Shahid, W., Abbasi, H. S., Nadeem, E., Siddiqui, E., Zafar, W., & Hussain, S. (2025) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-025-00727-y · Cited by 1
“The removal of the study by Perkovic et al. [19] reduced the heterogeneity, but the results still did not favor semaglutide significantly.”
Danneel, C., Sauvage, C., Hayef, M. N., Desmet, V., Surquin, M., Nortier, J., & Vriese, C. D. (2025) · Biomedicines · doi:10.3390/biomedicines13040994 · Cited by 2
“Semaglutide demonstrated positive effects in reducing the risk of clinically important renal events and cardiovascular death in patients with type 2 diabetes and CKD [29].”
Diabetic kidney disease: The fourth pharmacological pillar may be semaglutide
Giugliano, D., Esposito, K., & Nicola, L. D. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15892 · Cited by 1
Current Strategies for Preventing Diabetic Kidney Disease
Ghotekar, L. H., & Yadav, M. (2025) · International Journal of Advanced Medical and Health Research · doi:10.4103/ijamr.ijamr_153_24 · Cited by 1
COVID-19 Pandemic-induced Healthcare Disruption and Chronic Kidney Disease Progression
Liu, R., Abraham, R., Conderino, S. E., et al. (2025) · Journal of General Internal Medicine · doi:10.1007/s11606-025-09832-9 · Cited by 1
Inflammation as a therapeutic target to improve kidney and cardiovascular outcomes
Tuttle, K. R., Kanbay, M., Alicic, R. Z., Carrero, J. J., Çöpür, S., Navar, A. M., Neuen, B. L., Perkovic, V., Rossing, P. R., Marx, N., et al. (2026) · Nature Reviews Nephrology · doi:10.1038/s41581-026-01117-6 · Cited by 4
Self-citationTirzepatide, HFpEF, and the Kidney
ter Maaten, J. M., & Butler, J. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.03.508 · Cited by 1
Tekengne, B. O. T., Eke, C. I., Cumaaran, C., Ozigbo, A. A., Okoyeuzu, C., Okhagbuzo, I. M., Sadiq-Onilenla, R. A., & Okobi, O. E. (2025) · Cureus · doi:10.7759/cureus.91722 · Cited by 2
Theodorakis, N., Kreouzi, M., & Nikolaou, M. (2025) · Heart Failure Reviews · doi:10.1007/s10741-025-10506-1 · Cited by 3
Taal, M. W., Eldehni, M. T., & Selby, N. M. (2025) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2025.05.005 · Cited by 1
Obesity in Cardiorenal syndrome: Management Opportunities and Challenges
Reaves, A. C., Jaffe, E., & McCallum, W. I. (2025) · Current Hypertension Reports · doi:10.1007/s11906-025-01352-5 · Cited by 1
Dewar, S., Janevic, M. R., Batsis, J. A., & Alexander, N. B. (2025) · Current Developments in Nutrition · doi:10.1016/j.cdnut.2025.107526 · Cited by 3
“…the efficacy of semagLutide in chronic kidney disease Outing for patients with type 2 diabetes Worldwide (FLOW) trial demonstrated that a semaglutide at a lower dose of 1 mg weekly reduced the risk of clinically important kidney outcomes by 24% while slowing the chronic disease progression [31].”
KOVIL, R. R., Shah, T., Tanna, S., Negalur, V. B., PATANGE, S. A., Sanghvi, A., Manoria, P., TIWASKAR, M. H., PADHYE, D. A., Sowani, A., et al. (2025) · International Journal of Diabetes and Technology · doi:10.4103/ijdt.ijdt_22_25 · Cited by 2
Loizidis, G., & Summer, R. S. (2026) · Clinical Rheumatology · doi:10.1007/s10067-026-08212-w · Cited by 1
Allen, M. R., Metzger, C. E., Chen, N. X., Tinsley, I. C., DiMarchi, R. D., O’Neill, K. D., Matter, E. K., & Moe, S. M. (2026) · Bone · doi:10.1016/j.bone.2026.117933 · Cited by 2
Wyss, F. S., Ullauri, V. E., Lara-Terán, J. J., Arteaga-Arellano, A., Martín, C. G., López-Santi, R., Pérez, G., Madrigal, C. A., Ger, M., Piskorz, D. L., et al. (2026) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-026-02157-5 · Cited by 3
“GLP-1 RAs provide clinically meaningful reductions in kidney disease progression, cardiovascular events, and mortality in patients with type 2 diabetes and chronic kidney disease, with a favorable safety profile and preserved efficacy even in advanced CKD [196].”
Advances in Cardiorenal Medicine: The Year 2024 in Review
Kazory, A., & Ronco, C. (2025) · Cardiorenal Medicine · doi:10.1159/000544817 · Cited by 1
“The landmark FLOW (Evaluate Renal Function with Semaglutide Once Weekly) randomized controlled trial (RCT) assessed the ef fi cacy and safety of subcutaneous semaglutide in patients with type 2 diabetes and chronic kidney disease (CKD) [1].”
Schlaich, M. P., Abhayaratna, W. P., Audehm, R. G., Ekinci, E. I., MacIsaac, R. J., Nelson, A. J., Sharma, A., & Pollock, C. (2026) · Internal Medicine Journal · doi:10.1111/imj.70403 · Cited by 1
GLP-1 Receptor Agonists: Therapeutic Potential and Emerging Concerns
Nowak, K., Łupina, K., Kalisz, A., Ilkiewicz, Ł., & Janczura, J. (2026) · Current Pharmacology Reports · doi:10.1007/s40495-026-00459-w · Cited by 2
Fong, J. M. N., Low, S. K., Xu, Y., Teo, P. S. E., Lim, G. H., Zheng, H., Ang, K., Tan, N. C., Poh, C. B., Tay, H. B., et al. (2025) · Primary care diabetes · doi:10.1016/j.pcd.2025.02.005 · Cited by 1
Nguyen, T., Hong, L., & Iso, T. (2026) · Cardiorenal Medicine · doi:10.1159/000552517 · Cited by 1
Dalal, N., Saxena, A., Mohsen, A., Borgi, J., Tatum, D. M., & Divya, A. (2026) · JHLT Open · doi:10.1016/j.jhlto.2026.100565 · Cited by 1
“12,”
Workforce Detachment in Persons with CKD
Rørth, R., Koch, M. M., Gerds, T. A., Carlson, N., Rossing, P. R., Kümler, T., Torp-Pedersen, C. T., Køber, L., & Chertow, G. M. (2026) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000001003 · Cited by 2
Self-citationBae, J., Lee, M., Kim, H. W., Park, J. T., Han, S. H., Lee, B. I., Kang, E. S., Cha, B., Yoo, T., & Lee, Y. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70816 · Cited by 1
“…enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs) [6, 7], as well as sodium-glucose cotransporter-2 (SGLT-2) inhibitors [8, 9] and glucagon-like pep- tide-1 (GLP-1) receptor agonists, with recent evidence particularly for semaglutide [10], have demonstrated renoprotective effects.”
Lost in Stratification: Age Subgroup Analyses in CKD Progression Trials
Vart, P. (2026) · Kidney International Reports · doi:10.1016/j.ekir.2026.106684 · Cited by 1
Fish oil supplements in patients with chronic kidney disease
Ferro, C. J., Thomas, M. R., Khattak, S., Chanouzas, D., & Townend, J. (2026) · Clinical Kidney Journal · doi:10.1093/ckj/sfag168 · Cited by 1
“…the last few years there have been very significant advances in the treatment of CKD. Agents such as SGLT2-inhibitors [ 36 , 37 ], GLP-1 agonists [ 38 ], and finerenone [ 39 , 40 ], a non-steroidal mineralocorticoid receptor antagonist, have been shown to significantly reduce both the progression…”
Zhu, D., & Herrington, W. G. (2024) · Annals of Internal Medicine · doi:10.7326/annals-24-02457-jc · Cited by 1
Ruga, S., Matarese, E., Bava, R., Lombardi, C., Dimatteo, T., Miscio, L., Raponi, M., Giordano, A., Sansone, C., Liguori, G., et al. (2026) · Pharmaceuticals · doi:10.3390/ph19081230 · Cited by 1
Kuehn, B. M. (2025) · Kidney News · doi:10.62716/kn.000752025 · Cited by 1
Medical treatments for obesity: what does the future have in store?
Bassatne, A., & Rizo, I. M. (2026) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgag274 · Cited by 1
Ksiazek, S. H., Windpessl, M., Zitt, E., Rudnicki, M., Eller, K., Schwarz, C., Antlanger, M., Schmaldienst, S., Cejka, D., Oberbauer, R. W., et al. (2025) · Wiener klinische Wochenschrift · doi:10.1007/s00508-025-02590-y · Cited by 3
The landscape of renal protein S-acylation in mice with lipid-induced nephrotoxicity
Xiu, F., Gai, Z., Gehrig, P., Wolski, W., Lone, M. A., & Visentin, M. (2025) · Scientific Reports · doi:10.1038/s41598-025-92530-7 · Cited by 1
Nitric oxide redox signaling as a convergent mechanism in aging and fibrosis
Guo, X., Cao, Y., Liu, L., Peng, Y., Du, Y., Yang, F., & Huang, D. (2026) · Ageing Research Reviews · doi:10.1016/j.arr.2026.103156 · Cited by 1
Remission in diabetic kidney disease: current evidence and future directions
Reaume, M., & Tangri, N. (2026) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000001197 · Cited by 2
Sharma, A. R., Lázaro-Guevara, J. M., STUCKI, D., Anand, S., Welt, C. K., & Pezzolesi, M. G. (2026) · Journal of the Endocrine Society · doi:10.1210/jendso/bvag100
“Similarly, young adults comprised small subsets in cardiovascular and renal trials of glucagon-like peptide receptor agonists [23, 24].”
Diabetic kidney disease—Recent updates
Bloomgarden, Z. T. (2024) · Journal of Diabetes · doi:10.1111/1753-0407.13612 · Cited by 2
Chen, T., Tseng, C.-J., Li, Y., Lin, Y., Chen, D., Yang, N., Wang, T.-H., Hung, M., & Tsai, M. (2025) · Acta Diabetologica · doi:10.1007/s00592-024-02443-6 · Cited by 1
Neuen, B. L., & Solomon, S. D. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.07.002 · Cited by 2
Endocrinology: What You May Have Missed in 2024
Aman, M., Jeevananthan, A., Martinez-Cruz, M., Namasingh, N., & Batch, B. C. (2025) · Annals of Internal Medicine · doi:10.7326/annals-25-00990 · Cited by 1
Evaluation and management of aortic stenosis in chronic kidney disease
Mallick, S., Ogugua, F., Chedid, M., Mathew, R. O., & Shroff, G. R. (2024) · Journal of the Heart Valve Society · doi:10.1177/30494826241296668 · Cited by 1
Deciphering the Effects of Semaglutide Across the Glycemic Spectrum
Misra, S. (2024) · Diabetes Care · doi:10.2337/dci24-0057 · Cited by 3
Lee, Y. H., Kim, D. K., Kim, J. S., Jeong, S. J., Jeong, K. H., & Hwang, H. S. (2025) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1652372 · Cited by 2
“In addition, glucagon-like peptide-1 receptor agonists (GLP-1RAs) not only facilitate weight reduction but also confer renoprotective (36, 37), cardioprotective (38, 39), and anti-inflammatory effects (40).”
Maki, K. C., Dickinson, S., Kirkpatrick, C. F., Qu, Y., Arora, V., Chen, X., Ortyl, B. K., Landsittel, D. P., Ali, S., & Friedman, A. N. (2025) · Obesity Science & Practice · doi:10.1002/osp4.70109 · Cited by 1
“In addition to promoting weight loss, the results of randomized controlled trials have shown that GLP‐1 RAs and SGLT2 inhibitors improve kidney outcomes in T2D [38–42].”
Saraiva, J. F. K., Valério, C. M., Rached, F. H., van de Sande‐Lee, S., Rocha, V. Z., Valente, F., Drager, L. F., Halpern, B., Júnior, W. S. D. S., Trujilho, F. R., et al. (2025) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20250621 · Cited by 17
The Timeline of the Association Between Diabetes and Cardiovascular Diseases: A Narrative Review
Luca, S. A., Bungau, R. M., Lazăr, S., Herascu, A., Gaiţă, L., Avram, V. F., & Timar, B. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14196877 · Cited by 1
“…of CKD. Results demonstrated a significant decrease in kidney outcomes and CV death, along with a slower decline in renal function, lower MACE incidence, and lower mortality rates in patients treated with semaglutide, establishing its role as a potential treatment option in diabetic CKD [98].”
Komé, A. M., Yang, A., Gee, P. O., & Klein, K. R. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01705-y · Cited by 3
“Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) have also demonstrated kidney protective effects (in addition to their CV effects) in the FLOW clinical trial [14].”
Brož, J. (2025) · Vnitřní lékařství · doi:10.36290/vnl.2025.026 · Cited by 1
Ntelis, S., & Wojeck, B. S. (2025) · Current Hypertension Reports · doi:10.1007/s11906-025-01349-0 · Cited by 1
“In the FLOW trial [26] 3533 patients with T2DM and CKD were randomized to 1 mg semaglutide weekly or placebo.”
Chiang, Y.-L., Li, T.-H., Fang, Y.-W., Liu, Y.-F., Wu, J., & Tsai, M. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1801203 · Cited by 5
Sodium-Glucose Cotransporter 2 Inhibition and Hospitalizations in Patients with CKD
Oshima, M., Buizen, L., Jongs, N., Levin, A., Chertow, G. M., Wheeler, D. C., Heerspink, H. J. L., Arnott, C. G., Jardine, M., Mahaffey, K. W., et al. (2025) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000000771 · Cited by 1
Self-citationKuo, Y.-J., Chen, L.-F., Chen, Y., Chen, P., & Lin, H. Y. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27094120 · Cited by 4
Rosenzveig, A., Tefera, L. T., Agrawal, A., Rajendran, J., Massad, F., Badwan, O. Z., Wajsberg, J. R., Chaudhury, P., Zidar, D. A., Paul, T. K., et al. (2026) · Journal of the American Heart Association · doi:10.1161/jaha.125.045664 · Cited by 3
Metadata
- Authors
- Perkovic, V., Tuttle, K. R., Rossing, P., Mahaffey, K. W., Mann, J. F. E., Bakris, G., Baeres, F. M. M., Idorn, T., Bosch-Traberg, H., Lausvig, N. L., & Pratley, R.
- Affiliations
- University of Copenhagen (DK)
- Novo Nordisk A/S, Søborg, Denmark.
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2024-07-11
- Volume
- 391
- Issue
- 2
- Pages
- 109-121
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4398781461
- Cited by
- 2,099
- References
- 23
- Citations by year
- 2026: 953 · 2025: 863 · 2024: 281
- FWCI
- 551.63
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
- Digital Access to Libraries (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Funders
- Novo Nordisk A/S
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
- Keywords
- semaglutide, chronic kidney disease, type 2 diabetes, renal failure, estimated glomerular filtration rate decline, cardiovascular mortality, albuminuria, GLP-1 receptor agonists, renal protection, cardiovascular outcomes, albumin-creatinine ratio, kidney transplantation, dialysis, anemia of chronic kidney disease, diabetic nephropathy, SGLT2 inhibitors
- MeSH terms
- Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, Aged, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Diabetic Nephropathies, Double-Blind Method, Glucagon-Like Peptides, Female, Glomerular Filtration Rate, Humans, Hypoglycemic Agents, Injections, Subcutaneous, Male, Middle Aged, Renal Insufficiency, Chronic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.